Analysis of the degree of clinical suspect in patients with congenital adrenal hyperplasia by 21-hydroxylase deficiency before obtaining the result of the newborn screening program of the autonomous Community of Madrid.
e202012186
Keywords:
Congenital adrenal hyperplasia, 21 hydroxylase deficiency, Salt-wasting form, Simple virilizing form, Neonatal screening, Clinical suspicionAbstract
Background: The objective of this study was to analyze the clinical suspicion and where the patients were when they received the result of the neonatal screening for 21 hydroxylase deficiency (21OHD).
Methods: The present data were derived from a retrospective analysis of a group of patients with classical 21OHD discovered by newborn screening and treated at the Center for Clinical Follow-up of the Autonomous Community of Madrid. Stadistic analysis of the data was performed using version 15.5 of the SPSS® software.
Results: During the period from 1990 to 2015 of this study 46 children were diagnosed with classical 21OHD [36 with the salt-wasting (SW) and 10 with simple virilizing form (SV)]. The median age at diagnosis for the patients with the SW and SV form were 8.0 (6.0-9.0) and 18.0 (14.5–37.5) days respectively (P=0.001). In 35 (76.1%) patients the disease had not been suspected before the result of newborn screening, 28 patients affected by SW form, with a potential risk of death due to adrenal crisis (of which, in addition 6 women with incorrect assignment of sex at birth) and 7 patients affected with SV form. Two thirds of the patients with classic forms identified by neonatal screening were in their homes without suspicion of any disease or pending any additional study.
Conclusions: Neonatal screening provided better performance than clinical suspicion. In the majority of patients with 21OHD detected by newborn screening, the diagnosis by screening was anticipated to the clinical suspicion of the disease even in female patients with ambiguous genitalia.
Downloads
References
Honour JW TT. Evaluation of neonatal screening for congenital adrenal hyperplasia. Horm Res. 2001;55(4):206-11.
Brosnan CA BP, Swint JM. Analyzing the cost of neonatal screening for congenital adrenal hyperplasia. Pediatrics. 2001;107(5):1238.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010; 95: 4133-60.
Rodríguez Arnao MD, Rodríguez Sánchez A, Dulín Iñiguez: “Detección precoz de alteraciones endocrinas”. Rev Esp Endocrinol Pediatr. 2013; (Suppl):59-71.
A. Rodríguez Sánchez, M. Sanz Fernández, M. Echeverría Fernández. Pediatr Integral 2015; XIX (7): 488 – 497.
BL T. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001;30:15–30.
E D. La incidencia en España de la hiperplasia adrenal congénita (CAH). Prevención de Enfermedades Metabólicas 1989;3:11-3.
Hayashi G FC, Brondi MF, Vallejos C, Soares D, Oliveira E. Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn sreening for congenital adrenal hyperplasia. Arq Bras. 2011;55(8):632-7.
Van der Kamp HJ OC, Elvers BH, Vaharle MVB, Otten BJ, Wit JM et al. Cutoff Levels of 17-α-Hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab. 2005;90(7):3904-7.
Efectividad clínica del cribado neonatal de los errores congénitos del metabolismo mediante espectrometría de masas en tándem. Revisión sistemática. Ministerio de sanidad y consumo. 2007.
Dulin- Iniguez E EM, Eguileor-Gurtubai I Programas de cribado neonatal. An Pediatr Contin. 2006;4(1):61-5.
Grosse SD VVG. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res. 2007;67(6):284-91.
Khalid JM, Oerton JM, Dezateux C, Hindmarsh PC, Kelnar CJ, Knowles RL. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Arch Dis Child. 2012;97(2):101-6.
Hird BE, Tetlow L, Tobi S, Patel L, Clayton PE. No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening. Arch Dis Child. 2014;99(2):158-64.
Kaye CI, Accurso F, La Franchi S, Lane PA, Hope N, Sonya P et al. Newborn screening fact sheets. Pediatrics. 2006;118(3):e934-63.
Thil’en A NA, Hagenfeldt L, von Döbeln U, Guthenberg C, Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics. 1998 101(4).
BL T. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001;30:15–30.
Steigert M. High Reliability of Neonatal Screening for Congenital Adrenal Hyperplasia in Switzerland. J Clin Endocrinol Metab. 2002;87(9):4106-10.
Strnadova KA, Votava F, Lebl J, Muhl A, Item C, Bodamer OA et al. Prevalence of congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria. European journal of pediatrics. 2007;166(1):1-4.
Gidlöf S FH, Thilén A et al. One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol. 2013;1(1):35–42.
AL. RLMGC. Cribado neonatal de la hiperplasia suprarrenal congénita. Aplicabilidad en Galicia. Santiago de Compostela: Servicio Galego de Saúde, Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia. avalia-t. 2004;Serie Avaliación de Tecnoloxías. Informes; INF2004/03.
Downloads
Published
How to Cite
License
Copyright (c) 2020 María Sanz Fernández, Marina Mora Sitja, Lucía Carrascón González Pinto, Amparo Rodríguez Sánchez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
